4.2 Review

Germline and somatic mutations in meningiomas

期刊

CANCER GENETICS
卷 208, 期 4, 页码 107-114

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cancergen.2015.02.003

关键词

SMARCB1; SMARCE1; SUFU; AKT1; meningioma

资金

  1. Drug Discovery Initiative grant [2014A-05-016]
  2. Schwannomatosis Award from the Children's Tumor Foundation [2014-02-001]

向作者/读者索取更多资源

Meningiomas arise from the arachnoid layer of the meninges that surround the brain and spine. They account for over one third of all primary central nervous system tumors in adults and confer a significant risk of location-dependent morbidity due to compression or displacement. A significant increase in risk of meningiomas is associated with neurofibromatosis type 2 (NF2) disease through mutation of the NF2 gene. In addition, approximately 5% of individuals with schwannomatosis disease develop meningiomas, through mutation of the SWI/SNF chromatin remodeling complex subunit, SMARCB1. Recently, a second SWI/SNF complex subunit, SMARCE1, was identified as a cause of clear cell meningiomas, indicating a wider role for this complex in meningioma disease. The sonic hedgehog (SHH)-GLI1 signaling pathway gene, SUFU, has also been identified as the cause of hereditary multiple meningiomas in a large Finnish family. The recent identification of somatic mutations in components of the SHH-GLI1 and AKT1-MTOR signaling pathways indicates the potential for cross talk of these pathways in the development of meningiomas. This review describes the known meningioma predisposition genes and their links to the recently identified somatic mutations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Extended gene panel testing in lobular breast cancer

Elke M. van Veen, D. Gareth Evans, Elaine F. Harkness, Helen J. Byers, Jamie M. Ellingford, Emma R. Woodward, Naomi L. Bowers, Andrew J. Wallace, Sacha J. Howell, Anthony Howell, Fiona Lalloo, William G. Newman, Miriam J. Smith

Summary: The study found that in women with lobular breast cancer, pathogenic germline variants in genes other than BRCA1/2, such as ATM, also significantly increase the risk of the disease. Extended panel genetic testing can help improve early risk identification and intervention.

FAMILIAL CANCER (2022)

Article Genetics & Heredity

High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer

D. Gareth Evans, Elke Maria van Veen, Helen J. Byers, Sarah J. Evans, George J. Burghel, Emma Roisin Woodward, Elaine F. Harkness, Diana M. Eccles, Stephanie L. Greville-Haygate, Jamie M. Ellingford, Naomi L. Bowers, Marta Pereira, Andrew J. Wallace, Sasha J. Howell, Anthony Howell, Fiona Lalloo, William G. Newman, Miriam Jane Smith

Summary: The study shows that the rates of BRCA1, BRCA2, and TP53 PVs are high in very early onset breast cancer cases. Testing of additional breast cancer-associated genes did not provide significant benefits. BRCA1/2 PVs were more common in women aged 26-30 years compared to younger women, and the younger age group had rates similar to other study cohorts.

JOURNAL OF MEDICAL GENETICS (2022)

Article Oncology

PTCH2 is not a strong candidate gene for gorlin syndrome predisposition

Miriam J. Smith, D. Gareth Evans

Summary: Upon evaluating 21 PTCH1/SUFU negative GS families, no pathogenic PTCH2 variants were identified, nor could previously published PTCH2 variants be considered pathogenic based on current guidelines. The absence of clear pathogenic variants in GS families and the high frequency of LoF variants in the general population suggest PTCH2 should not be included in panels for genetic diagnosis of GS.

FAMILIAL CANCER (2022)

Article Genetics & Heredity

Dominant-negative pathogenic variant BRIP1 c.1045G>C is a high-risk allele for non-mucinous epithelial ovarian cancer: A case-control study

Nicola Flaum, Elke M. van Veen, Olivia Smith, Stephanie Amico, William G. Newman, Emma J. Crosbie, Richard Edmondson, Miriam J. Smith, D. Gareth Evans

Summary: BRIP1 gene variants are associated with the risk of breast cancer and/or ovarian cancer, with the c.1045G>C variant showing a higher risk, especially for women with EOC. The study underscores the importance of BRIP1 as an EOC susceptibility gene, particularly in familial cases.

CLINICAL GENETICS (2022)

Article Genetics & Heredity

Comparison of the frequency of loss-of-function LZTR1 variants between schwannomatosis patients and the general population

Fanxuan Deng, D. Gareth Evans, Miriam J. Smith

Summary: Schwannomatosis is a rare tumor predisposition syndrome that is difficult to classify and interpret the clinical significance of novel variants. Current classification guidelines can accurately identify most pathogenic variants, but there is a high frequency of LoF LZTR1 variants in the general population, making classification of novel variants challenging.

HUMAN MUTATION (2022)

Article Genetics & Heredity

Cancer risk and tumour spectrum in 172 patients with a germline SUFU pathogenic variation: a collaborative study of the SIOPE Host Genome Working Group

Lea Guerrini-Rousseau, Julien Masliah-Planchon, Sebastian M. Waszak, Pia Alhopuro, Patrick R. Benusiglio, Franck Bourdeaut, Ines B. Brecht, Giada Del Baldo, Sandeep Kumar Dhanda, Maria Luisa Garre, Corrie E. M. Gidding, Steffen Hirsch, Pauline Hoarau, Mette Jorgensen, Christian Kratz, Lucie Lafay-Cousin, Angela Mastronuzzi, Lorenza Pastorino, Stefan M. Pfister, Christopher Schroeder, Miriam Jane Smith, Pia Vahteristo, Roseline Vibert, Catheline Vilain, Nicolas Waespe, Ingrid M. Winship, D. Gareth Evans, Laurence Brugieres

Summary: This study found that carriers of germline SUFU pathogenic variants have a lifelong increased risk of tumors, with medulloblastoma being dominant before the age of 5, gonadal tumors during adolescence, and basal cell carcinoma and meningioma in adulthood. These findings emphasize the need for fine-tuned surveillance programs.

JOURNAL OF MEDICAL GENETICS (2022)

Article Genetics & Heredity

SMARCE1 deficiency generates a targetable mSWI/SNF dependency in clear cell meningioma

Roodolph St Pierre, Clayton K. Collings, Daniel D. Same Guerra, Christian J. Widmer, Olubusayo Bolonduro, Nazar Mashtalir, Akshay Sankar, Yu Liang, Wenya Linda Bi, Erica H. Gerkes, Vijaya Ramesh, Jun Qi, Miriam J. Smith, David M. Meredith, Cigall Kadoch

Summary: SMARCE1 loss destabilizes the canonical BAF complex and increases the formation of BRD9-containing non-canonical (ncBAF) complexes. This study reveals a structural role for SMARCE1 in stabilizing the canonical BAF complex on chromatin and identifies potential therapeutic approaches for SMARCE1-deficient clear cell meningioma tumors.

NATURE GENETICS (2022)

Article Oncology

A mechanistic mathematical model of initiation and malignant transformation in sporadic vestibular schwannoma

Chay Paterson, Ivana Bozic, Miriam J. Smith, Xanthe Hoad, D. Gareth R. Evans

Summary: This study presents a mechanistic approach to modeling the initiation and malignant transformation of vestibular schwannoma, resulting in new parameter estimates. The results suggest that radiotherapy may have a negligible excess risk of malignancy for sporadic vestibular schwannoma.

BRITISH JOURNAL OF CANCER (2022)

Article Dermatology

Germline intergenic duplications at Xq26.1 underlie Bazex-Dupre-Christol basal cell carcinoma susceptibility syndrome

Yanshan Liu, Siddharth Banka, Yingzhi Huang, Jonathan Hardman-Smart, Derek Pye, Antonio Torrelo, Glenda M. Beaman, Marcelo G. Kazanietz, Martin J. Baker, Carlo Ferrazzano, Chenfu Shi, Gisela Orozco, Stephen Eyre, Michel van Geel, Anette Bygum, Judith Fischer, Zosia Miedzybrodzka, Faris Abuzahra, Albert Rubben, Sara Cuvertino, Jamie M. Ellingford, Miriam J. Smith, D. Gareth Evans, Lizelotte J. M. T. Weppner-Parren, Maurice A. M. van Steensel, Iskander H. Chaudhary, D. Chas Mangham, John T. Lear, Ralf Paus, Jorge Frank, William G. Newman, Xue Zhang

Summary: This study identifies small tandem noncoding intergenic duplications at chromosome Xq26.1 as the cause of Bazex-Dupre-Christol syndrome (BDCS). These duplications likely dysregulate the flanking centromeric gene ARHGAP36. Loss-of-function variants in ACTRT1 are unlikely to cause BDCS.

BRITISH JOURNAL OF DERMATOLOGY (2022)

Article Genetics & Heredity

High detection rate from genetic testing in BRCA-negative women with familial epithelial ovarian cancer

Nicola Flaum, Emma J. Crosbie, Richard Edmondson, Emma R. Woodward, Fiona Lalloo, Miriam J. Smith, Helene Schlecht, D. Gareth Evans

Summary: This study reviewed the genetic testing of women with familial epithelial ovarian cancer (EOC) at a center. One-fifth of BRCA-negative women carried potentially actionable gene variants. Wider genetic testing of women with familial EOC is essential for optimizing treatment and preventing disease in family members.

GENETICS IN MEDICINE (2022)

Article Clinical Neurology

Genome-wide association analysis identifies a susceptibility locus for sporadic vestibular schwannoma at 9p21

Katherine Sadler, John Bowes, Charlie F. Rowlands, Cristina Perez-Becerril, C. Mwee van der Meer, Andrew T. King, Scott A. Rutherford, Omar N. Pathmanaban, Charlotte Hammerbeck-Ward, Simon K. W. Lloyd, Simon R. Freeman, Ricky Williams, Cathal John Hannan, Daniel Lewis, Steve Eyre, D. Gareth Evans, Miriam J. Smith

Summary: A genome-wide association study revealed that rs1556516 in the 9p21.3 region is associated with the risk of vestibular schwannoma. The dysregulation of CDKN2B-AS1 and CDKN2A/B genes in this region has been linked to multiple pathologies, and these genes have been shown to influence each other's expression. The recurrent associations of the 9p21.3 region with known oncogenic pathways provide compelling evidence for its involvement in vestibular schwannoma tumorigenesis.
Article Genetics & Heredity

Differential rates of germline heterozygote and mosaic variants in NF2 may show varying propensity for meiotic or mitotic mutation

D. Gareth Evans, George J. Burghel, Miriam Jane Smith

Summary: NF2-related schwannomatosis is a genetic condition that causes multiple benign tumors of the nervous system. It is caused by pathogenic variants in the NF2 gene, with six specific CpG nonsense variants being responsible for a majority of the cases. The de novo heterozygote to mosaicism ratio of one of these variants, NF2 c.586C>T; p.(Arg196Ter), is higher compared to the others, possibly due to variations in mutation rates during meiosis and mitosis.

JOURNAL OF MEDICAL GENETICS (2023)

Article Genetics & Heredity

Differential involvement of germline pathogenic variants in breast cancer genes between DCIS and low-grade invasive cancers

D. Gareth Evans, Siva Sithambaram, Elke Maria van Veen, George J. Burghel, Helene Schlecht, Elaine F. Harkness, Helen Byers, Jamie M. Ellingford, Ashu Gandhi, Sacha J. Howell, Anthony Howell, Claire Forde, Fiona Lalloo, William G. Newman, Miriam Jane Smith, Emma Roisin Woodward

Summary: This study aimed to investigate the frequency of germline pathogenic variants (PVs) in women with ductal carcinoma in situ (DCIS) and grade 1 invasive breast cancer (G1BC). The results showed that DCIS was more likely to be associated with both BRCA1/2 and non-BRCA1/2 PVs than G1BC. Extended panel testing is recommended for young-onset DCIS where PV detection rates are highest.

JOURNAL OF MEDICAL GENETICS (2023)

Article Oncology

Perspectives on the implications of carrying putative pathogenic variants in the medulloblastoma predisposition genes ELP1 and GPR161

Miriam J. Smith, Emma R. Woodward, D. Gareth Evans

Summary: Recent genetic sequencing studies have identified loss-of-function variants in the ELP1 and GPR161 genes as causes of childhood medulloblastoma. Although there is speculation that GPR161 may also cause Gorlin syndrome, the projected risks of developing medulloblastoma with these gene variants are relatively low and do not warrant MRI screening in infants.

FAMILIAL CANCER (2023)

Article Genetics & Heredity

Validation of lung cancer polygenic risk scores in a high-risk case-control cohort

Mikey B. Lebrett, Miriam J. Smith, Emma J. Crosbie, John Bowes, Helen J. Byers, Gareth Evans, Philip A. J. Crosbie

Summary: The study investigated the performance of previously published polygenic risk scores (PRSs) for lung cancer (LC) and found that genetic variables could be used for screening selection and potentially improve screening effectiveness. Among the 9 PRSs validated in a high-risk case-control cohort, the best-performing PRS had an independent high area under the curve (AUC). Two novel loci, in the DAPK1 and MAGI2 genes, were significantly associated with LC risk. These findings suggest that PRSs may improve LC risk prediction and screening selection.

GENETICS IN MEDICINE (2023)

暂无数据